EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, UroGen Pharma's enterprise value is $533.53 Mil.
UroGen Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $91.87 Mil. Therefore, UroGen Pharma's EV-to-Revenue for today is 5.81.
The historical rank and industry rank for UroGen Pharma's EV-to-Revenue or its related term are showing as below:
URGN'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.95 Med: 8.03 Max: 31601.59
Current: 5.81
During the past 10 years, the highest EV-to-Revenue of UroGen Pharma was 31601.59. The lowest was 0.95. And the median was 8.03.
URGN's EV-to-Revenue is ranked better than 56.02% of 996
companies
in the Biotechnology industry
Industry Median: 7.685
vs URGN: 5.81
As of today (2025-06-28), UroGen Pharma's stock price is $13.49.
UroGen Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $2.03. Therefore, UroGen Pharma's PS Ratio for today is 6.65.
UroGen Pharma EV-to-Revenue Historical Data
The historical data trend for UroGen Pharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of UroGen Pharma's EV-to-Revenue
For the Biotechnology subindustry, UroGen Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's EV-to-Revenue falls into.
UroGen Pharma's current Enterprise Value is $533.53 Mil.
UroGen Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $91.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma's share price for today is $13.49.
UroGen Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of UroGen Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
URGN has been successfully added to your 